About the speaker
Andreas Katopodis studied molecular biology and immunology. After five years at the Georgia Institute of Technology in Atlanta, he moved to the Ciba Geigy Zentrale Forschungslaboratorien in Basel, doing research on immune cell trafficking. With the creation of Novartis, he moved to the Novartis Autoimmunity, Transplantation and Inflammation group where he was involved in many aspects of early to late drug development for immune mediated diseases, such as solid organ transplantation and autoimmunity. In 2018, he co-founded Anaveon to pursue the development of immune stimulating pathways for the rejection of tumors.